Evidence map›Paper›PMID 41514577›Full record

ArticleCancers2025

BRG1 (SMARCA4) Status Dictates the Response to EGFR Inhibitors in Wild-Type EGFR Non-Small Cell Lung Cancer.

Rebaz Ahmed, Ranganayaki Muralidharan, Narsireddy Amreddy, Akhil Srivastava, Meghna Mehta, Janani Panneerselvam, Rodrigo Orlandini de Castro, William L Berry, Susmita Ghosh, Murali Ragothaman and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rebaz AhmedDepartment of Pathology, The University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.
Ranganayaki MuralidharanDepartment of Pathology, The University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.
Narsireddy AmreddyDepartment of Pathology, The University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.
Akhil SrivastavaDepartment of Pathology, The University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.ORCID 0000-0003-2015-259X
Meghna MehtaDepartment of Radiation Oncology, The University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.
Janani PanneerselvamDepartment of Pathology, The University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.
Rodrigo Orlandini de CastroCell Cycle and Cancer Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
William L BerryDepartment of Surgery, The University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.ORCID 0000-0002-1661-5443
Susmita GhoshDepartment of Pathology, The University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.ORCID 0000-0001-6591-9147
Murali RagothamanDepartment of Pathology, The University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.ORCID 0000-0002-4813-1232
Pawan AcharyaBiostatistics and Epidemiology, The University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.
Yan D ZhaoOU Health Stephenson Cancer Center, The University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.
Roberto Jose PezzaCell Cycle and Cancer Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
Anupama MunshiDepartment of Radiation Oncology, The University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.
Rajagopal RameshDepartment of Pathology, The University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.ORCID 0000-0002-7658-5338

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Wade Williams · 2018 to 2026
$27.1M
Exosomes as carriers of cancer therapeuticsR01CA254192 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI RAMESH, RAJAGOPAL · 2021 to 2025
$2.8M
Engineered Nanoformulation for Immune-modulation in CancerR01CA282735 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Rajagopal Ramesh · 2023 to 2026
$2.2M
National Insitutes of Health R01CA254192NCI NIH HHS P30 CA225520NCI NIH HHS R01 CA254192NCI NIH HHS R01 CA282735NIH HHS P30CA225520NIH HHS R01CA282735
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BRG1EGFRlung cancerresistanceSMARCA4therapytyrosine kinase inhibitor

Identifiers

PMID41514577
PMCPMC12784900

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.